Hormone replacement therapy and prevention of chronic conditions

被引:17
|
作者
Gambacciani, M. [1 ]
Cagnacci, A. [2 ]
Lello, S. [3 ]
机构
[1] Univ Hosp Pisa, Dept Obstet & Gynecol, Pisa, Italy
[2] Univ Udine, Dept Obstet & Gynecol, Udine, Italy
[3] Policlin Gemelli, Dept Obstet & Gynecol, Rome, Italy
关键词
Menopause; hormone replacement therapy; osteoporosis; cardiovascular disease; hypertension; CORONARY-HEART-DISEASE; POSTMENOPAUSAL ESTROGEN THERAPY; BLOOD-PRESSURE; FOLLOW-UP; CARDIOVASCULAR MORTALITY; MYOCARDIAL-INFARCTION; TIMING HYPOTHESIS; PARADIGM SHIFT; WOMEN; MENOPAUSE;
D O I
10.1080/13697137.2018.1551347
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Nowadays, postmenopausal women are largely undertreated. Analysis of conflicting results among different studies suggests that hormone replacement therapy (HRT) can prevent osteoporosis and cardiovascular disease in symptomatic, early postmenopausal women. In fact, climacteric symptoms are related to an increased risk of chronic conditions, including hypertension and cardiovascular disease. Different scientific societies have pointed out that patient selection, timing of initiation, and the choice of the type and dose of HRT used are the major determinants of the ultimate effect of HRT on women's health and quality of life in selected women. HRT may prevent chronic conditions when started in symptomatic women before the age of 60years or within 10years of the onset of the menopause, taking into consideration the characteristics and risk profiles of each given woman. The bulk of scientific evidence from preclinical, clinical, epidemiological, and also randomized studies indicates that wisely selected HRT is generally useful and rarely dangerous. Following simple and well-established rules, HRT benefits outweigh all of the possible risks. Progestogen choice can make the difference in terms of cardiovascular disease benefits.
引用
收藏
页码:303 / 306
页数:4
相关论文
共 50 条
  • [21] Hormone replacement therapy 2004 - The dilemma
    Flatau, E
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2004, 6 (10): : 642 - 642
  • [22] The ethics of aggregation and hormone replacement therapy
    Lyerly, AD
    Myers, ER
    Faden, RR
    HEALTH CARE ANALYSIS, 2001, 9 (02) : 187 - 211
  • [23] Hormone replacement therapy - Current recommendations
    Vigneswaran, Kugajeevan
    Hamoda, Haitham
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2022, 81 : 8 - 21
  • [24] Menopause and hormone replacement therapy.
    Tellier, P
    Godeau, P
    REVUE DE MEDECINE INTERNE, 2000, 21 (05): : 445 - 457
  • [25] Hormone replacement therapy and cardiovascular prevention. Where are we now?
    Lerman, Jorge
    Siseles, Nestor
    MEDICINA-BUENOS AIRES, 2008, 68 (03) : 251 - 257
  • [26] Menopause in 2004: "hormone replacement therapy" is not what it used to be anymore
    Azoulay, C
    REVUE DE MEDECINE INTERNE, 2004, 25 (11): : 806 - 815
  • [27] Coronary heart disease and hormone replacement therapy after the menopause
    Hodis, H. N.
    Mack, W. J.
    CLIMACTERIC, 2009, 12 : 71 - 75
  • [28] An update on menopausal hormone replacement therapy in women and cardiovascular disease
    Valdiviezo, Carolina
    Lawson, Shari
    Ouyang, Pamela
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2013, 20 (02) : 148 - 155
  • [29] The Ethics of Aggregation and Hormone Replacement Therapy
    Anne Drapkin Lyerly
    Evan R. Myers
    Ruth R. Faden
    Health Care Analysis, 2001, 9 : 187 - 211
  • [30] The Controversial History of Hormone Replacement Therapy
    Cagnacci, Angelo
    Venier, Martina
    MEDICINA-LITHUANIA, 2019, 55 (09):